Ticker - Embedded Expectations Analysis - Date
Teva Pharmaceutical Industries Limited (TEVA:USA) currently trades below recent averages relative to UAFRS-based (Uniform) Earnings, with an 18.0x Uniform P/E, implying bearish expectations for the firm. Furthermore, management may be concerned about EPS, product launches, and future litigations.Specifically, management is confident there are a lot of ongoing opioid-related cases, and they appear concerned about the sustainability of recent operating profit, net income, and EPS. Additionally, they may be concerned about the value of their portfolio optimization efforts, and they may lack confidence in their ability to improve their operating margin. Furthermore, management may be concerned about their ability to receive FDA approval for their AJOVY auto-injector, and they may be concerned about the sustainability of recent AUSTEDO prescription and sales growth. Finally, they may be concerned about future litigations, and they may be concerned about the timing of their generic Forteo and NuvaRing launches.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.